According to Zacks, “Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. “
Other analysts also recently issued research reports about the stock. JMP Securities cut their price objective on shares of Evolus from $35.00 to $30.00 and set a “market outperform” rating for the company in a report on Tuesday, August 13th. They noted that the move was a valuation call. Mizuho reissued a “buy” rating and issued a $30.00 price objective on shares of Evolus in a report on Thursday, September 5th. ValuEngine downgraded shares of Evolus from a “buy” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Co began coverage on shares of Evolus in a report on Friday, June 28th. They issued a “market perform” rating and a $16.00 price objective for the company. Finally, Stifel Nicolaus set a $33.00 price objective on shares of Evolus and gave the company a “buy” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. Evolus currently has a consensus rating of “Buy” and a consensus target price of $26.67.
Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Monday, August 12th. The company reported ($1.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.41). The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $0.29 million. On average, sell-side analysts expect that Evolus will post -4.28 EPS for the current year.
Several institutional investors have recently modified their holdings of EOLS. Point72 Asset Management L.P. bought a new stake in shares of Evolus during the 2nd quarter worth approximately $4,167,000. Vanguard Group Inc. lifted its holdings in shares of Evolus by 46.3% during the 2nd quarter. Vanguard Group Inc. now owns 710,230 shares of the company’s stock worth $10,384,000 after acquiring an additional 224,758 shares during the period. BlackRock Inc. lifted its holdings in shares of Evolus by 12.2% during the 2nd quarter. BlackRock Inc. now owns 994,396 shares of the company’s stock worth $14,540,000 after acquiring an additional 107,946 shares during the period. Wafra Inc. lifted its holdings in shares of Evolus by 106.2% during the 2nd quarter. Wafra Inc. now owns 203,263 shares of the company’s stock worth $2,972,000 after acquiring an additional 104,706 shares during the period. Finally, Segantii Capital Management Ltd bought a new stake in shares of Evolus during the 2nd quarter worth approximately $1,097,000. 19.20% of the stock is owned by institutional investors.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Story: How is the Producer Price Index calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.